U.S. markets closed

Mind Medicine (MindMed) Inc. (MMED.NE)

NEO - NEO Real Time Price. Currency in CAD
Add to watchlist
3.1000-0.0500 (-1.59%)
At close: 3:56PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.1500
Open3.2100
Bid3.0500 x N/A
Ask3.1400 x N/A
Day's Range3.0600 - 3.2100
52 Week Range0.5500 - 5.9900
Volume211,767
Avg. Volume616,149
Market Cap1.142B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.2120
Earnings DateNov 11, 2021 - Nov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • PR Newswire

      MindMed to Present at H.C. Wainwright 23rd Annual Global Investment Conference

      Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. Members of management will also be available to speak with institutional investors in one-on-one virtual meetings throughout the conference.

    • PR Newswire

      MindMed to Attend 8th Annual "Mobile in Clinical Trials" Conference

      Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its Chief Medical Officer, Daniel R. Karlin, MD MA, will co-chair the 8th annual Mobile in Clinical Trials Conference, which will be held virtually on September 27, 2021 and is a partner program to the 2021 DPharm Conference.

    • PR Newswire

      MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes

      MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, and BioXcel Therapeutics, Inc. ("BioXcel"), a leading clinical-stage biopharmaceutical company, announce the publication of BioXcel's International Patent Application No. PCT/US2020/051256 (published as WO2021055595) for detecting and preventing the early onset of agitation in patients predisposed to highly agitated behaviour. The disclosure provides a method for mea